Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study by van Os, Jim et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/125229/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
van Os, Jim, Pries, Lotta­Katrin, Delespaul, Philippe, Kenis, Gunter, Luykx, Jurjen J., Lin, Bochao
D., Richards, Alexander L., Akdede, Berna, Binbay, Tolga, Altınyazar, Vesile, Yalınçetin, Berna,
Gümüş­Akay, Güvem, Cihan, Burçin, Soygür, Haldun, Ulaş, Halis, Cankurtaran, Şahin, Kaymak,
Semra Ulusoy, Mihaljevic, Marina M., Petrovic, Sanja Andric, Mirjanic, Tijana, Bernardo, Miguel,
Cabrera, Bibiana, Bobes, Julio, Saiz, Pilar A., García­Portilla, María Paz, Sanjuan, Julio, Aguilar,
Eduardo J., Santos, José Luis, Jiménez­López, Estela, Arrojo, Manuel, Carracedo, Angel, López,
Gonzalo, González­Peñas, Javier, Parellada, Mara, Maric, Nadja P., Atbaşoğlu, Cem, Ucok, Alp,
Alptekin, Köksal, Saka, Meram Can, Arango, Celso, O'Donovan, Michael, Rutten, Bart P. F. and
Guloksuz, Sinan 2019. Replicated evidence that endophenotypic expression of schizophrenia
polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene­
environment interaction. The EUGEI study. Psychological Medicine 10.1017/S003329171900196X
file 
Publishers page: http://dx.doi.org/10.1017/S003329171900196X
<http://dx.doi.org/10.1017/S003329171900196X>
Please note: 
Changes made as a result of publishing processes such as copy­editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
1 
 
Evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy 
siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI 
study. 
 
Jim van Os1,2,3*; Lotta-Katrin Pries2; Philippe Delespaul2; Gunter Kenis2; Jurjen J. Luykx1,4; Bochao D. 
Lin1; Alexander L. Richards5; Berna Akdede6; Tolga Binbay6; Vesile Altınyazar7; Berna Yalınçetin8; 
Güvem Gümüş-Akay9; Burçin Cihan10; Haldun Soygür11; Halis Ulaş11; Eylem Şahin Cankurtaran12; 
Semra Ulusoy Kaymak13; Marina M. Mihaljevic14, 15; Sanja Andric Petrovic15; Tijana Mirjanic16; Miguel 
Bernardo17,18,19; Bibiana Cabrera17,19; Julio Bobes19, 20, 21, 22; Pilar A. Saiz19, 20, 21, 22; María Paz García-
Portilla19, 20, 21, 22;  Julio Sanjuan19, 23; Eduardo J. Aguilar19, 23; José Luis Santos19,24; Estela Jiménez-
López19, 25; Manuel Arrojo26; Angel Carracedo27; Gonzalo López19, 28; Javier González-Peñas19, 28; Mara 
Parellada19, 28; Nadja P. Maric14, 15; Cem Atbaşoğlu29; Alp Ucok30; Köksal Alptekin6; Meram Can Saka29; 
Genetic Risk and Outcome Investigators (GROUP)#; Celso Arango19, 28; Michael O’Donovan5; Bart P. F. 
Rutten2; Sinan Guloksuz2,31 
Affiliations 
1 Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht 
University, Utrecht, the Netherlands  
2 Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, 
Maastricht University Medical Center, Maastricht, the Netherlands 
3 King's College London, King's Health Partners, Department of Psychosis Studies, Institute of 
Psychiatry, London, United Kingdom  
4 Department of Translational Neuroscience, Brain Center Rudolf Magnus, University Medical Center 
Utrecht, Utrecht University, Utrecht, the Netherlands  
5 MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and 
Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, United Kingdom 
6 Department of Psychiatry, Dokuz Eylul University School of Medicine, Izmir, Turkey 
7 Department of Psychiatry, Faculty of Medicine, Adnan Menderes University, Aydin, Turkey. 
8 Department of Neuroscience, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey 
9 Ankara University Brain Research Center, Ankara, Turkey 
10 Department of Psychology, Middle East Technical University  
11 Private practice 
12 Güven Çayyolu Healthcare Campus, Ankara, Turkey  
13 Atatürk Research and Training Hospital Psychiatry Clinic, Ankara, Turkey 
14 Faculty of Medicine, University of Belgrade 
15 Clinic for Psychiatry CCS, Belgrade, Serbia 
16 Special Hospital for Psychiatric Disorders Kovin, Kovin, Serbia 
17 Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, University 
of Barcelona, Spain 
18 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain 
19 Biomedical Research Networking Centre in Mental Health (CIBERSAM), Spain. 
20 Department of Psychiatry, School of Medicine, University of Oviedo, Spain 
21 Instituto de Investigación Sanitaria del Principado de Asturias, ISPA, Spain  
22 Mental Health Services of Principado de Asturias, SESPA; Oviedo, Spain 
2 
 
23 Department of Psychiatry, Hospital Clínico Universitario de Valencia, School of Medicine, 
Universidad de Valencia, INCLIVA, Valencia, Spain.  
24 Department of Psychiatry, Hospital Virgen de la Luz, Cuenca, Spain 
25 Universidad de Castilla-La Mancha, Health and Social Research Center, Cuenca, Spain 
26 Department of Psychiatry, Instituto de Investigación Sanitaria (IDIS), Complejo Hospitalario 
Universitario de Santiago de Compostela, SERGAS, Santiago de Compostela, Spain 
27 Fundación Publica Galega de Medicina Xenómica, Hospital Clínico Universitario de Santiago de 
Compostela, Universidad de Santiago de Compostela, Santiago de Compostela, Spain 
28 Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, 
IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain. 
29 Department of Psychiatry, School of Medicine, Ankara University, Ankara, Turkey 
30 Istanbul University, Istanbul Faculty of Medicine, Department of Psychiatry 
31 Department of Psychiatry, Yale School of Medicine, New Haven, CT  
 
# Genetic Risk and Outcome of Psychosis (GROUP) Investigators in EUGEI 
 
GROUP-EUGEI investigators are: Behrooz Z. Alizadeha, Therese van Amelsvoortb, Richard 
Bruggemana, Wiepke Cahne,f, Lieuwe de Haang, Bart P.F. Ruttenh, Jurjen J. Luykxe,i, Jim van Ose,h,j, 
Ruud van Winkelh,k 
 
a University of Groningen, University Medical Center Groningen, University Center for Psychiatry, 
Rob Giel Research center, Groningen, The Netherlands; 
b Maastricht University Medical Center, Department of Psychiatry and Neuropsychology, School for 
Mental Health and Neuroscience, Maastricht, The Netherlands; 
e University Medical Center Utrecht, Department of Psychiatry, UMC Utrecht Brain Centre, Utrecht 
University, Utrecht, The Netherlands; 
f Altrecht, General Menthal Health Care, Utrecht, The Netherlands 
g Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, The 
Netherlands; 
hMaastricht University Medical Center, Department of Psychiatry and Neuropsychology, School for 
Mental Health and Neuroscience, Maastricht, The Netherlands; 
i GGNet Mental Health, Apeldoorn, The Netherlands 
j King’s College London, King’s Health Partners, Department of Psychosis Studies, Institute of 
Psychiatry, London, United Kingdom 
kKU Leuven, Department of Neuroscience, Research Group Psychiatry, Leuven, Belgium; 
 
 
Acknowledgements 
This work was supported by the European Network of National Schizophrenia Networks Studying 
Gene-Environment Interactions (EUGEI) Project is funded by grant agreement HEALTH-F2-2010-
241909 (Project EUGEI) from the European Community’s Seventh Framework Programme. We thank 
the patients and their families for participating in the EUGEI project. We also would like to thank all 
research personnel involved in the GROUP project, in particular:  Joyce van Baaren, Erwin Veermans, 
Ger Driessen, Truda Driesen, Erna van ’t Hag, Jessica de Nijs. All the DNA samples from Turkey were 
3 
 
provided by Ankara University Brain Research Center Biobank that was supported by AUBAPRO 
(10A6055003). 
 
Correspondence:  
Jim van Os 
Department of Psychiatry 
UMC Utrecht Brain Centre 
Utrecht University Medical Centre 
PO BOX 85500 | 3508 GA Utrecht, The Netherlands 
T: +31 88 75 583 46 | j.j.vanos-2@umcutrecht.nl 
 
Figure: 1 
Tables: 8 
Supplementary Figures: 0 
Supplementary Tables: 0  
Word count text: 4678  
  
4 
 
Abstract 
BACKGROUND.  
First-degree relatives of patients with psychotic disorder have higher levels of polygenic risk (PRS) for 
schizophrenia and higher levels of intermediate phenotypes.  
METHODS 
We conducted, using two different samples for discovery (n=336 controls and 649 siblings of 
patients with psychotic disorder) and replication (n=1208 controls and 1106 siblings), an analysis of 
association between PRS on the one hand and psychopathological and cognitive intermediate 
phenotypes of schizophrenia on the other in a sample at average genetic risk (healthy controls) and 
a sample at higher than average risk (healthy siblings of patients). Two subthreshold psychosis 
phenotypes, as well as a standardized measure of cognitive ability, based on a short version of the 
WAIS-III short form, were used. In addition, a measure of jumping to conclusion bias (replication 
sample only) was tested for association with PRS.  
RESULTS 
In both discovery and replication sample, evidence for association between PRS and subthreshold 
psychosis phenotypes was observed in the relatives of patients, whereas in the controls no 
association was observed. Jumping to conclusion bias was similarly only associated with PRS in the 
sibling group. Cognitive ability was weakly negatively and non-significantly associated with PRS in 
both the sibling and the control group.  
CONCLUSIONS 
The degree of endophenotypic expression of schizophrenia polygenic risk depends on having a 
sibling with psychotic disorder, suggestive of underlying gene-environment interaction. Cognitive 
biases may better index genetic risk of disorder than traditional measures of neurocognition, which 
instead may reflect the population distribution of cognitive ability impacting the prognosis of 
psychotic disorder.  
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Introduction 
Although there is a growing number of studies on the impact of schizophrenia-associated genetic 
variation on intermediate phenotypes of schizophrenia (Hatzimanolis et al., 2018, Hatzimanolis et 
al., 2015, Jones et al., 2016, Mistry et al., 2017, Nivard et al., 2017, Power et al., 2015, Riglin et al., 
2017, van Os et al., 2017), more work is required, particularly in order to obtain exact rather than 
approximate replication (Kapur et al., 2012). In a previous publication, we showed that genetic 
variation underlying psychosis spectrum disorder was associated with suggested intermediate 
phenotypes of psychopathology and cognition in a sample of first degree relatives of patients, who 
have a higher than average genetic and environmental liability, and healthy comparison participants 
with average genetic liability (van Os et al., 2017). Although the earlier study had adequate sample 
size, any study in this area is crucially dependent on exact replication with similar measures and 
study design. The aim of this publication, therefore, was to produce an exact replication study, 
repeating the previous discovery analysis, comparing similar groups and using the same self-report 
and interview measures of psychopathology and cognition to analyse associations with the 
schizophrenia polygenic risk score (PRS), using the latest available GWAS summary statistics from the 
Psychiatric Genomics Consortium wave-2 SCZ group as a training set. As our previous study indicated 
differential patterns of association between relatives and healthy comparison participants, which is 
in line with the concept that relatives can be expected to show stronger endophenotypic 
associations than healthy comparison participants, we tested for interactions with relative/control 
status. The replication sample was derived from Workpackage 6 (GxE Vulnerability & Severity) of the 
international EUGEI study (European Network of National Networks studying Gene-Environment 
Interactions in Schizophrenia et al., 2014), consisting of 1525 healthy comparison participants and 
1282 siblings of patients.  
Cognitive vulnerabilities underlying psychosis include cognitive biases such as jumping to conclusion 
bias, in addition to traditional measures of neurocognition (McLean et al., 2017). Given that jumping 
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to conclusion bias may be more prevalent in first-degree relatives of patients (Van Dael et al., 2006), 
and no previous study has tested for molecular genetic association with these cognitive biases, we 
examined, in the replication sample, for association between PRS and a measure of jumping to 
conclusion bias. 
Thus, in the current paper, we analyse associations between PRS on the one hand and measures of 
psychopathology, neurocognition and jumping to conclusion bias in siblings of patients with a 
psychotic disorder and healthy comparison subjects. As described above, two samples were used. 
The first sample, referred to as the ‘GROUP discovery sample’ is a re-analysis of our previously 
published results in the GROUP sample  (van Os et al., 2017). The second sample, referred to as the 
‘EUGEI replication sample’ is the analysis of the more recent EUGEI sample. 
 
Method 
Samples 
EUGEI replication sample 
The EUGEI project is a 25-centre, 15-country, EU-funded collaborative network studying the impact 
of genetic and environmental factors on the onset, course and neurobiology of psychosis spectrum 
disorder (European Network of National Networks studying Gene-Environment Interactions in 
Schizophrenia et al., 2014). Workpackage 6, entitled ‘Vulnerability and Severity’, focussed on the 
psychometric expression of genetic and environmental liability in the siblings of patients, who are at 
higher than average genetic and environmental risk compared to well healthy comparison 
participants. The sample in Workpackage 6 was collected in Spain (5 centres), Turkey (3 centres) and 
Serbia (1 centre) and consisted of 1525 healthy comparison participants, 1261 patients with a 
diagnosis of psychosis spectrum disorder (average duration of illness since age of first contact with 
mental health services: 9.9 years) and 1282 siblings of these patients. Exclusion criteria for all 
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participants were diagnosis of psychotic disorders due to another medical condition, history of head 
injury with loss of consciousness, and intelligence quotient < 70. The current analyses were 
restricted to the group of healthy comparison participants and the siblings. Individuals of non-white 
ethnic group (n=30) were excluded, as were individuals with missing GWAS information (n=463), 
leaving 2314 participants (1208 healthy comparison participants and 1106 relatives) for the current 
analysis.  
To achieve high quality and homogeneity in clinical, experimental, and environmental assessments, 
standardized instruments were administered by psychiatrists, psychologists, or trained research 
assistants who completed mandatory on-site training sessions and online training modules including 
interactive interview videos and self-assessment tools (European Network of National Networks 
studying Gene-Environment Interactions in Schizophrenia et al., 2014). Both on-site and online 
training sessions were repeated annually to maintain high inter-rater reliability throughout the study 
enrollment period (for details see: https://cordis.europa.eu/result/rcn/175696_en.html). 
The EUGEI project was approved by the Medical Ethics Committees of all participating sites and 
conducted in accordance with the Declaration of Helsinki. All respondents provided written 
informed consent and, in the case of minors, such consent was also obtained from parents or legal 
guardian. 
GROUP discovery sample 
The current paper also present a re-analysis of the discovery sample, presented in detail in a 
previous publication, pertaining to the GROUP study, an ongoing multicentre study in the 
Netherlands of patients diagnosed with schizophrenia and related disorder, as well as their siblings, 
parents and healthy participants (Korver et al., 2012, van Os et al., 2017). The current analysis in the 
GROUP sample focussed on 336 healthy comparison participants and 649 siblings of patients, who 
were assessed three times over a period of six years, yielding 2416 observations. 
8 
 
Allowing for true replication from GROUP discovery to EUGEI replication sample 
In order to allow for true replication in the original discovery sample of the Dutch GROUP study, 
differences between the previous GROUP study and the current EUGEI study that were under our 
control were dissolved. Thus, one possible reason for discrepancy between studies using polygenic 
risk for schizophrenia is difference in the platform for molecular genetic analysis used, as well as 
difference in the version of the GWAS summary statistics from the training sample (Psychiatric 
Genomics Consortium wave-2 SCZ group). In order to neutralise these factors, GWAS was repeated 
in the GROUP sample (data version 7.0), using the same genetic analysis platform as used in the 
current (and later) EUGEI study. Similarly, quality control and calculation of polygenic scores was 
done in the same fashion as the EUGEI study. In addition, a standardized cognitive score was 
calculated in the GROUP sample, based on the same variables as in the EUGEI sample. In addition, 
the same comparison between healthy comparison participants and healthy siblings of patients was 
conducted. Previous publications in the GROUP sample have shown significant differences between 
healthy comparison participants and siblings in the measures of CAPE and SIS-R psychosis proneness 
used in the current analysis, with siblings displaying higher values (Genetic Risk and Outcome in 
Psychosis Investigators, 2011). 
 
Measures 
The GROUP discovery and EUGEI replication samples used the same instruments as listed below, 
with the exception of the beads task, which was used only in the EUGEI replication sample. 
Interview-based schizotypy: SIS-R 
The SIS-R was administered to healthy comparison participants, parents and siblings. The SIS-R is a 
semi-structured interview containing 20 schizotypal symptoms and 11 schizotypal signs rated on a 4-
point scale (Kendler et al., 1989, Vollema and Ormel, 2000). Symptoms are defined as verbal 
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responses to standardized questions concerning, for example, magical ideation, illusions, and 
referential thinking. Signs refer to behaviours that are rated by the interviewer such as goal-
directedness of thinking and flatness of affect. Questions and rating procedures are standardized. 
Guided by previous research, 33 item scores were reduced a priori to 2 dimensional scores, 
representing the means of 7 positive schizotypy items (covering the areas of referential thinking, 
psychotic phenomena, derealisation, magical ideation, illusions, and suspiciousness) and 8 negative-
disorganized schizotypy items (covering the areas of social isolation, sensitivity, introversion, 
restricted affect, disturbances in associative and goal-directed thinking, poverty of speech, and 
eccentric behaviour). 
 
Self-reported psychotic experiences: CAPE 
The Community Assessment of Psychic Experiences (CAPE; www.cape42.homestead.com) was 
developed to rate self-reports of lifetime psychotic experiences (Konings et al., 2006). Items are 
modelled on patient experiences as contained in the Present State Examination, 9th version (Wing et 
al., 1974), schedules assessing negative symptoms such as the Scale for the Assessment of Negative 
Symptoms (SANS) (Andreasen, 1982) and the Subjective Experience of Negative Symptoms (SENS) 
(Selten et al., 1993), and scales assessing depressive symptoms such as the Calgary Depression Scale 
(Addington et al., 1993). Items are scored on a 4-point scale. In the current analyses, CAPE 
dimensions of frequency of positive experiences (20 items), negative experiences (14 items) and 
depressive experiences (8 items) were included (measured at baseline and 3-year follow-up), 
representing the person’s perceived psychosis load over the lifetime (at baseline) or in the past 
three years (follow-up). A total score representing the mean of all items was calculated for each 
dimension.  
Cognitive score 
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Cognition ability was estimated based on a short version of the WAIS-III short form: the Digit Symbol 
Coding subtest, uneven items of the Arithmetic subtest, uneven items of the Block Design subtest, 
every third item of the Information subtest (Blyler et al., 2000, Velthorst et al., 2013, Wechsler, 
1997). For each test, the Z-score was calculated separately for each country and sex. The cognition 
score was the mean of the Z-scores of the different tests, expressed as a T-score (cognition score 
shifted and scaled to have a mean of 50 and a standard deviation of 10). The measure will be 
referred hereafter as ‘cognitive score’. 
Beads task (EUGEI replication sample only) 
The beads task (Phillips and Edwards, 1966) is an experimental test designed to measure individuals’ 
reasoning style under ambiguous conditions. It was administered only in the replication sample 
(EUGEI study). A computerised version of the beads task was completed to assess the presence or 
absence of the Jumping to Conclusions (JTC) bias. Participants were shown two jars containing red 
and blue coloured beads in opposite ratios. In this study, the ratio of 60 to 40 beads was chosen, 
resulting in 100 beads in each jar. The jars as well as all instructions were presented on a computer 
screen. After both jars were shown and a training session was completed, participants were 
instructed that all beads are drawn consecutively from one jar and, once presented, were returned 
to the same jar. After each draw, participants were asked whether they wanted to see another bead 
or make a decision on which jar the beads were drawn, with the possibility to see up to 20 beads 
before a decision had to be made. The order of presented beads was predetermined and the 
dominant colour presented in the training session selected at random. The number of beads drawn 
at was considered to represent individuals’ reasoning style, and used as dependent variable in the 
analyses. 
Genotyping, imputation and polygenic risk scores 
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Samples of all individuals, i.e. pertaining to both the discovery and the replication sample, were 
genotyped at Cardiff University Institute of Psychological Medicine and Clinical Neurology, using 
custom Illumina HumanCoreExome-24 BeadChip genotyping arrays containing probes for 570038 
genetic variants (Illumina, San Diego, CA). Genotype data were called using the GenomeStudio 
package and transferred into PLINK format for further analysis.   
Genotype quality control – variants 
Quality control was conducted in PLINK v1.07 (Purcell et al., 2007) or with custom Perl scripts. 
Variants with call rate < 98% were excluded from the dataset. Hardy-Weinberg Equilibrium p-value 
was calculated separately in Turkish, northern European and southern European samples. Variants 
with Hardy-Weinberg Equilibrium p-value < 1e-6 in any of these three regions were excluded from 
the dataset. After QC, 559505 variants remained. 
Genotype quality control – samples 
Samples with call rate < 98% were excluded from the dataset. A linkage disequilibrium pruned set of 
variants was calculated using the --indep-pairwise command in PLINK (maximum r2 = 0.25, window 
size = 500 SNPs, window step size = 50 SNPs) and used for further analyses. Homozygosity F values 
were calculated using the --het command in PLINK, and outlier samples (F < -0.11 or F > 0.15) were 
excluded. The genotypic sex of samples was calculated from X chromosome data using the --check-
sex command in PLINK, and samples with different genotypic sex to their database sex were 
excluded. 
Identity-by-descent (IBD) values were calculated for the sample in PLINK. Samples with 1 or more 
siblings among the genotyped samples according to the database but no identified genotypic siblings 
(defined as PI-HAT > 0.35 and < 0.65) were excluded. After these were removed from consideration, 
samples with 2 or more database siblings in the database that were not supported by the genotypic 
data were also excluded. 
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After visually observing clustering of errors by genotyping chip, we decided to exclude chips with a 
high proportion of errors. All samples on chips with 5 or more sample exclusions due to 
heterozygosity or call rate (out of 12 possible samples) were excluded. All samples on chips with 4 or 
more sample exclusions due to sex or relative checks were also excluded, unless their identity was 
corroborated by concordance between database and genotype relatedness data with a sample on 
another chip. 
Principal component analysis 
Principal components (PCs) were calculated in PLINK using LD pruned variants after combining the 
dataset with the Thousand Genomes reference dataset. Due to the inherently multi-population 
nature of the dataset and the variety of possible analyses, no exclusions were made to the whole 
dataset based on this analysis; population effects were corrected for separately in individual 
analyses. 
Imputation 
After quality control, genotypes were imputed on the Michigan Imputation Server using the 
Haplotype Reference Consortium reference panel (version 1.1) and the programs Eagle for 
haplotype phasing and Minimac3 for imputation(Das et al., 2016, Loh et al., 2016). After imputation, 
variants with an imputation r2 > 0.6, MAF > 0.1% and call rate > 99% were retained (8277535 
variants). Best-guess genotypes were generated from genotype probabilities using PLINK.  
Polygenic risk score calculation 
PRS-SCZ was constructed using summary statistics from the PGC2 genome-wide association study, 
excluding samples present in the GROUP data (Schizophrenia Working Group of the Psychiatric 
Genomics Consortium, 2014). Clumping was performed in imputed best-guess genotypes for each 
dataset using PLINK (maximum r2 = 0.2, window size = 500kb, minimum MAF = 10%, minimum INFO 
score = 0.7), and variants within regions of long-range LD around the genome (including the MHC) 
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excluded (Price et al., 2008). PRS-SCZ were then constructed from best-guess genotypes using PLINK 
at 10 different p-value thresholds (PT=1, 0.5, 0.3, 0.2, 0.1, 0.05, 0.01, 1x10-4, 1x10-6, 5x10-8). We used 
PT=0.05 for our primary analysis, as this threshold explained the most variation in the phenotype in 
the PGC2 analysis(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). 
In the EUGEI WP6 dataset, the number of siblings and controls for whom a polygenic risk score could 
be thus constructed, after QC and imputation, and after exclusion of non-white ethnic groups was: 
1106 and 1208, respectively. In the GROUP dataset, a polygenic risk score could be similarly 
computed for 649 siblings and 336 healthy comparison participants, after exclusion of non-white 
groups. 
Analyses 
EUGEI WP6 database version 1.0 And GROUP database version 7.0 were used for the analyses. 
Bivariate scatterplots were constructed for SIS-R scores, CAPE scores, cognitive score and beads task 
on the one hand, and PRS on the other. Random intercept multilevel regression models (taking into 
account clustering of participants within families as well as within countries and, in the re-analysis of 
the discovery sample, clustering of repeated measures within participants) with SIS-R scores, CAPE 
scores, cognitive score and beads task as dependent variables were fitted using the MIXED routine in 
the Stata program, version 15 (StataCorp, 2017). Independent variables were polygenic risk score, a 
priori corrected for age and sex, while all models including PRS were additionally adjusted for 
ancestry, using the first 10 PCs.  
In order to examine robustness of findings with regard to assumptions of normality, log-transformed 
outcomes of SIS-R scores, CAPE scores, cognitive score and beads task were additionally examined, 
using the Stata LNSKEW0 routine. LNSKEW0 creates newvar = ln(+/-exp - k), choosing k and the sign 
of exp so that the skewness of newvar is zero. 
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In order to examine to what degree the size of any association between PRS and measures of 
psychopathology/cognition would be stronger for siblings than for healthy comparison subjects,   
interactions were fitted between group (healthy comparison participant/relative status) and 
continuous PRS. Interaction analyses were followed by calculation of polygenic risk score effect sizes, 
stratified by group (i.e. calculating associations between PRS and measures of 
psychopathology/cognition separately for siblings and healthy comparison subjects) , derived from 
the model with the interaction, using the STATA MARGINS command.  
In line with Rothman (Rothman, 1990), corrections for multiple testing were not applied. Instead, we 
relied on a discussion of coherence and possible unifying pattern of results. 
 
Results 
EUGEI replication sample description 
Relatives and healthy comparison participants showed similar demographic characteristics and 
cognitive scores. These variables also showed comparable distributions across the different 
countries, although participants tended to be younger in Serbia and the proportion of women was 
smaller in Spain (Table 1). Polygenic risk score scores were higher in Turkey, similar across the sexes 
and higher in the siblings (Table 2). Siblings had a higher schizophrenia polygenic risk score than 
healthy participants (standardized effect size: 0.06, p=0.006). Scores of SIS-R and CAPE were similar 
for men and women, with the exception of the CAPE depressive dimension, which was higher for 
women. Siblings had significantly higher scores on CAPE and SIS-R measures, with the exception of 
the CAPE positive dimension, probably due to defensive answering (data not shown) (for 
descriptives see Tables 3 and 4). 
Association between polygenic risk score and group in the EUGEI replication sample 
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Scatter plots of CAPE, SIS-R and cognitive dimensions on the one hand and polygenic risk score on 
the other generally showed that (i) the direction of association differed between siblings and healthy 
comparison subjects and (ii) siblings displayed stronger associations, with the exception of cognitive 
score (Fig. 1). Accordingly, all multilevel regression models of (log-transformed) SIS-R, CAPE and 
cognitive scores showed significant interaction between polygenic risk score and group, with the 
exception of CAPE positive dimension and cognitive score (Table 5). Stratified analyses revealed 
significant or suggestive positive associations between PRS and SIS-R and CAPE measures (with the 
exception of the CAPE positive dimension), and a negative association with beads task number of 
beads in the siblings. In the healthy comparison participants, there was either no association (CAPE 
measures) or a weak, directionally inverse association (SIS-R measures, beads task)(Table 6). 
Cognitive scores showed a different pattern, with weak negative associations with polygenic risk in 
both the sibling and the control groups. 
Re-analysis of original GROUP discovery sample 
Re-analysis of the GROUP discovery sample, using repeated measures of CAPE, SIS-R and cognitive 
score (calculated so as to match the cognitive score in the EUGEI study) in 985 healthy participants 
and siblings of patients  (n=336 healthy comparison participants and n=649 siblings), interviewed 
three times in 6 years, yielding 2416 observations, revealed results that were similar, in terms of 
direction, effect size and pattern of associations, to the current EUGEI study (Tables 7 and 8). Thus, 
again with the exception of cognitive score, there were significant interactions for the majority of 
psychopathological measures indicating no, or weakly negative association in the healthy participant 
group and significant associations in the sibling group (Tables 7 and 8). There was no association 
between cognitive score and PRS, and only in the sibling group was the association with cognitive 
score in the same (negative) direction as in the EUGEI replication sample (Tables 7 and 8). 
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Discussion 
In a replication study, using similar sampling and methodological strategies across samples, we 
found that polygenic risk for schizophrenia was associated with intermediate phenotype measures 
of psychopathology in non-ill participants. However, the pattern of association was differential for 
groups at average and higher than average genetic risk, showing stronger and directionally dissimilar 
associations in the sibling group compared to the healthy comparison group. A similar pattern of 
differential association was present for a measure of cognitive bias (jumping to conclusions). For a 
measure indexing cognitive ability, the EUGEI replication sample but not the GROUP discovery 
sample showed non-significant associations in both the sibling and the healthy comparison group, 
with no suggestion of interaction.  
The EUGEI replication findings thus match the results in the GROUP discovery sample (van Os et al., 
2017), re-analysed to match the methods of genetic examination in the EUGEI replication sample. 
We conclude that when using similar instruments and genetic measures, associations between 
polygenic risk score and psychosis intermediate phenotypes can be reliably replicated from one 
sample to another, in that associations are readily detectable in the group at higher than average 
genetic risk, but not, or inversely, in the group at average genetic risk. Overall, the findings suggest, 
with the exception of the measure of neurocognition, a pattern of qualitative interaction: 
associations between PRS and psychosis intermediate phenotypes tend to be positive in relatives of 
patients (PRS predicting poorer outcome) and negative in healthy comparison participants (PRS 
predicting better outcome). 
Polygenic risk and measures of psychopathology and cognition 
As far as we are aware, there have been no previous studies differentially examining polygenic risk in 
individuals at higher than average genetic risk in relation to psychopathology and cognition 
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intermediate phenotypes. Studies in healthy participants have shown inconsistent results 
(Hatzimanolis et al., 2018, Hatzimanolis et al., 2015, Jones et al., 2016, Mistry et al., 2017, Nivard et 
al., 2017, Riglin et al., 2017), one study notably reporting negative associations between polygenic 
risk and schizotypy, similar to the current results (Hatzimanolis et al., 2018). Another recent general 
population study found a protective effect of PRS in that PRS predicted greater levels of positive 
affect in daily life (Pries et al., 2019).  It is likely that crucial variation may be occasioned by platform 
for genetic analysis and calculation of polygenic risk score. Other factors may include quality 
checking of GWAS and variation in sampling, instruments and analysis. The results suggest that 
linking intermediate phenotypes to molecular measures of risk can be reliably achieved in 
moderately large samples of individuals at higher than average genetic risk. According to the 
liability-threshold model, a person with a number of risk variants lower than or equal to the critical 
threshold would not develop schizophrenia, whereas a person with more risk variants would (McGue 
et al., 1983). Given genetic enrichment in the relatives, this model may explain why polygenic risk 
was associated with psychometric and cognitive bias intermediate phenotypes in the relatives, but 
not in the healthy comparison participants. The current findings also indicate that self-report 
measures function less well than interview-based measures in uncovering associations between 
psychometric measures and polygenic risk for schizophrenia. Indeed, the findings suggest that 
siblings in the EUGEI replication sample showed a degree of defensive answering on the CAPE 
positive dimensions, scoring lower than the healthy comparison participants (Table 3), which was 
not the case in the discovery sample (van Os et al., 2017). 
The positive association between polygenic risk and the jumping to conclusion bias confirms 
previous results of familial clustering with psychosis (Van Dael et al., 2006). This result suggests that 
genetic variation may impact psychopathology by moderating underlying styles of thinking which are 
thought to interact with underling biological mechanisms in creating clinically relevant psychotic 
symptoms (Howes and Murray, 2014). 
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Qualitative interactions 
The results suggest that the degree of endophenotypic expression of polygenic molecular genetic 
risk crucially depends on having a first-degree relative with psychotic disorder, i.e. of having higher 
than average genetic risk for psychotic disorder. In the absence of a sibling with psychotic disorder, 
expression of polygenic risk may even be protective against expression of psychosis proneness, as 
also reported by other groups (Hatzimanolis et al., 2018, Pries et al., 2019). The notion of 
schizophrenia genetic risk having advantage may explain why all humans are carriers of a rich variety 
of schizophrenia genetic risk variants (Kendler, 2015) that, in addition, in the rare instances where it 
has been examined, may for example contribute to abilities required for a creative profession 
(Power et al., 2015). If polygenic risk for schizophrenia reduces the likelihood of schizophrenia-
related intermediate phenotypes in non-ill people, siblings should display even lower levels of 
expression of these intermediate phenotypes, which, however, was not the case. One factor that 
may explain the differential association as a function of familial presence of psychotic disorder is the 
environment. Thus, the siblings growing up with a brother or sister diagnosed with psychotic 
disorder have a higher rate of exposure to known proxy environmental risk factors such as urban 
environment and ethnic group – which are almost always shared between siblings, but also to risk 
factors like cannabis use and childhood adversity (Heins et al., 2011, Smith et al., 2008). Although 
presence of family history is generally taken as an indicator of increased genetic risk, research 
suggests that molecular measures of polygenic risk explain only around a fifth of the effect of family 
history, suggesting a substantial part may be explained by epistasis and/or environmental effects 
and the interactions between genes and environment (Agerbo et al., 2015). Schizophrenia may be in 
part dependent on gene-environment interplay, amongst others in the form of differential sensitivity 
to environmental risks (van Os et al., 2010), as indeed shown in a recent analysis of the same EUGEI 
sample (Guloksuz et al., 2019). Thus, siblings may have higher rates of expression of psychosis 
intermediate phenotypes not because of higher levels of genetic risk, but because of genetic risk 
interacting with higher rates of exposure to environmental risks in this group. Another possibility, 
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not mutually exclusive with gene-environment interplay, is that siblings share gene-gene 
interactions with their ill relatives that are uncommon in healthy controls, producing a qualitatively 
different pattern of association with intermediate phenotypes. 
Cognitive ability and lack of association and qualitative interaction 
Cognitive ability was the only measure where there was no clear pattern of association or qualitative 
interaction in both samples. Results in the largest sample showed weak and directionally similar 
negative associations between schizophrenia polygenic risk and cognition in both the healthy 
comparison and the sibling group. These findings are in line with previous population-based work 
showing similar weak negative associations between schizophrenia polygenic risk and measures of 
cognition, indicative of shared common genetic factors between schizophrenia and cognitive ability 
(Hubbard et al., 2016, Lencz et al., 2014). One explanation for the observed contrast in qualitative 
interaction between cognitive and non-cognitive intermediate phenotypes is prognostic 
confounding, or the fact that variation in cognition as observed in schizophrenia may represent a 
‘prognostic’ rather than a ‘disease’ factor. It has been pointed out that schizophrenia represents the 
poor outcome fraction of a much broader psychosis phenotype (Guloksuz and van Os, 2018). One of 
the factors driving prognostic variation in the psychosis spectrum is the degree of comorbid 
cognitive alterations. If the poor outcome end of the spectrum is defined as a separate disease, of 
which cognitive alteration is considered a key characteristic, prognostic confounding will arise. In 
other words, psychosis spectrum disorder may have a poorer outcome when it occurs in people who 
are at the lower end of the distribution of cognitive ability in the general population. This will 
occasion an association between schizophrenia genetic risk and cognition if the disease phenotype is 
conflated with the prognostic characteristic. As a result, schizophrenia genetic risk will predict lower 
cognitive ability in the general population – but to a similar degree in controls and siblins of patients. 
This interpretation is in line with recent work indicating that cognition in patients with schizophrenia 
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is more strongly associated with polygenic risk that indexes cognitive traits in the general population 
than polygenic risk from mental disorders (Richards et al., 2019). 
Methodological issues 
The strength of the current study is twofold: within-report true replication and unique large samples 
of individuals at higher-than average risk. We controlled for potential weaknesses such as the use of 
a multi-country sample with possible residual underlying population stratification. Future research 
may include more objective physiological intermediate phenotypes such as EEG or MRI-based 
measures. A limitation is that the current study lacked statistical power to conduct genome-wide 
analyses of association with endophenotypic measures, which would have allowed for GWAS 
stratified by sibling status as a confirmatory strategy.  
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Table 1. Sample demographics and cognitive scores, by group and country 
Group Age Sex Educational level Cognitive score Beads task number drawn N 
 
mean Sd % female mean sd Mean sd Mean Sd 
 
Healthy comparison participants 34.17 10.44 0.48 3.68 1.17 50.10 7.21 5.76 3.58 1,208 
Siblings 34.26 9.46 0.53 3.75 1.19 50.44 7.92 4.32 4.71 1,106 
Total 34.21 9.98 0.51 3.72 1.18 50.26 7.59 5.09 4.20 2,314* 
           
Country           
Turkey 33.81 10.45 0.54 3.75 1.18 50.31 7.89 5.25 4.01 1,424 
Spain 35.56 9.18 0.44 3.66 1.19 50.24 7.00 4.93 4.45 802 
Serbia 29.28 6.81 0.57 3.59 1.07 49.59 7.27 4.23 4.52 100 
Total 34.21 9.98 0.51 3.72 1.18 50.26 7.56 5.09 4.20 2,326* 
 
sd = standard deviation 
N = number of observations 
* 12 individuals had unknown group status 
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Table 2. Polygenic scores by country, sex and group 
Group  Country and sex 
 
 Turkey 
 
Spain 
 
Serbia 
 
 
 Men Women Men Women Men Women 
 
 
      
Healthy 
comparison 
participants 
Mean -16.53 -16.4 -19.73 -20.25 -18.83 -19.26 
sd 2.47 2.42 2.67 2.51 2.02 2.3 
N 361 435 241 123 20 26  
       
Siblings Mean -15.52 -15.84 -19.29 -19.52 -19.03 -18.41 
sd 2.45 2.45 2.54 2.55 2.64 2.23 
N 299 329 196 226 23 31 
 
sd = standard deviation 
N = number of observations 
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Table 3. CAPE scores by group and sex 
 CAPE positive score CAPE negative core CAPE depressive 
score 
CAPE total score 
 
mean sd N mean Sd N mean sd N mean sd N 
Group 
            
Healthy 
comparison 
participants 
0.26 0.29 1186 0.46 0.39 1186 0.52 0.40 1189 0.41 0.32 1186 
Siblings 0.23 0.21 1001 0.53 0.38 1002 0.59 0.39 1003 0.45 0.29 1001 
Total 0.24 0.26 2187 0.49 0.38 2188 0.56 0.40 2192 0.43 0.30 2187 
 
            
Sex             
Men 0.25 0.25 1070 0.49 0.37 1070 0.50 0.35 1071 0.41 0.28 1070 
Women 0.24 0.26 1114 0.49 0.40 1115 0.61 0.43 1118 0.45 0.32 1114 
Total 0.24 0.26 2184 0.49 0.38 2185 0.56 0.40 2189 0.43 0.30 2184 
 
sd = standard deviation 
N = number of observations   
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Table 4. SIS-R scores by group and sex 
 
SIS-R positive score SIS-R negative score SIS-R total score 
 
mean sd N mean sd N mean sd N 
Group 
         
Healthy 
comparison 
participants 0.22 0.3 1201 0.22 0.24 1196 0.22 0.23 1199 
Siblings 0.42 0.42 1074 0.45 0.37 1013 0.43 0.35 1021 
Total 0.31 0.38 2275 0.33 0.33 2209 0.32 0.31 2220  
         
Sex          
Men 0.31 0.37 1121 0.33 0.34 1084 0.32 0.31 1093 
Women 0.31 0.38 1151 0.33 0.32 1122 0.32 0.31 1124 
Total 0.31 0.38 2272 0.33 0.33 2206 0.32 0.31 2217 
 
sd = standard deviation 
N = number of observations  
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Table 5. Associations between polygenic risk score and CAPE / SIS-R / Cognitive (bias) scores, and interaction with healthy comparison-sibling status 
Psychopathology measure polygenic risk score x healthy comparison-sibling status interaction 
 B (95% CI) p N 
CAPE positive -0.0007 -0.0079 0.0064 0.8442 2184 
ln_CAPE positive* 0.0177 -0.0039 0.0392 0.1083 2184 
CAPE negative 0.0161 0.0053 0.0268 0.0034 2185 
ln_CAPE negative* 0.0218 0.0098 0.0339 0.0004 2185 
CAPE depressive 0.0091 -0.0019 0.0202 0.1057 2189 
ln_CAPE depressive* 0.0125 0.0001 0.0249 0.0474 2189 
CAPE total 0.0081 -0.0005 0.0166 0.0646 2184 
ln_CAPE total* 0.0163 0.0039 0.0288 0.0103 2184 
SIS-R positive 0.0308 0.0210 0.0407 0.0000 2272 
ln_SIS-R positive* 0.0881 0.0602 0.1160 0.0000 2272 
SIS-R negative 0.0235 0.0148 0.0321 0.0000 2206 
ln_SIS-R negative* 0.0544 0.0355 0.0732 0.0000 2206 
SIS-R total 0.0270 0.0189 0.0350 0.0000 2217 
ln_SIS-R total* 0.0637 0.0452 0.0823 0.0000 2217 
Cognitive score 0.0249 -0.1836 0.2335 0.8147 2160 
ln_Cognitive score* 0.0002 -0.0018 0.0021 0.8761 2160 
Beads task score -0.3810 -0.4956 -0.2664 0.0000 2219 
ln_Beads task score -0.1218 -0.1516 -0.0919 0.0000 2219 
 
* = log-transformed measure 
B=regression coefficient from multilevel model 
95% CI = 95% confidence interval 
P = p-value 
N = number of observations 
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Table 6. Associations between polygenic risk score and measures of psychopathology, by group* 
Psychopathology measure Stratified association of psychopathology 
measure with polygenic risk score 
Association of log-transformed 
psychopathology measure with polygenic 
risk score 
Group B (95% CI) p N B (95% CI) p N 
CAPE positive Healthy comparison 0.0021 -0.0036 0.0078 0.4671 2184 -0.0039 -0.0209 0.0131 0.6543 2184 
Sibling 0.0014 -0.0046 0.0074 0.6514 2184 0.0138 -0.0042 0.0318 0.1340 2184 
CAPE negative Healthy comparison -0.0032 -0.0117 0.0053 0.4568 2185 -0.0062 -0.0157 0.0033 0.1999 2185 
Sibling 0.0128 0.0039 0.0218 0.0050 2185 0.0156 0.0056 0.0257 0.0023 2185 
CAPE depressive Healthy comparison -0.0005 -0.0092 0.0083 0.9183 2189 -0.0027 -0.0124 0.0071 0.5937 2189 
Sibling 0.0087 -0.0006 0.0179 0.0659 2189 0.0099 -0.0005 0.0202 0.0611 2189 
CAPE total Healthy comparison -0.0004 -0.0071 0.0064 0.9123 2184 -0.0032 -0.0130 0.0066 0.5250 2184 
Sibling 0.0077 0.0005 0.0148 0.0351 2184 0.0131 0.0027 0.0235 0.0133 2184 
SIS-R positive Healthy comparison -0.0089 -0.0168 -0.0010 0.0273 2272 -0.0296 -0.0520 -0.0073 0.0094 2272 
Sibling 0.0219 0.0138 0.0300 0.0000 2272 0.0585 0.0355 0.0815 0.0000 2272 
SIS-R negative Healthy comparison -0.0063 -0.0131 0.0005 0.0711 2206 -0.0155 -0.0304 -0.0005 0.0426 2206 
Sibling 0.0172 0.0100 0.0243 0.0000 2206 0.0389 0.0232 0.0546 0.0000 2206 
SIS-R total Healthy comparison -0.0069 -0.0133 -0.0005 0.0355 2217 -0.0203 -0.0350 -0.0056 0.0067 2217 
Sibling 0.0201 0.0134 0.0268 0.0000 2217 0.0434 0.0280 0.0588 0.0000 2217 
Cognitive score Healthy comparison -0.1939 -0.3605 -0.0273 0.0225 2160 -0.0018 -0.0034 -0.0002 0.0262 2160 
Sibling -0.1690 -0.3401 0.0022 0.0531 2160 -0.0016 -0.0032 0.0000 0.0484 2160 
Beads task Healthy comparison 0.0806 -0.0102 0.1714 0.0818 2219 0.0270 0.0034 0.0506 0.0250 2219 
Sibling -0.3004 -0.3957 -0.2051 0.0000 2219 -0.0948 -0.1196 -0.0700 0.0000 2219 
 
* as derived from linear combination of terms in the model with the interaction 
B=regression coefficient from multilevel model 
95% CI = 95% confidence interval 
P = p-value 
N = number of observations 
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Table 7. Genetic Risk and Outcome of Psychosis (GROUP) sample: Associations between polygenic risk score and CAPE / SIS-R / Cognitive scores, and 
interaction with Healthy comparison-sibling status 
Psychopathology measure polygenic risk score x healthy comparison-sibling status interaction 
 B (95% CI) p N# 
CAPE positive 0.0125 0.0051 0.0200 0.0010 2324 
ln_CAPE positive* 0.0831 0.0369 0.1293 0.0004 2324 
CAPE negative 0.0196 0.0016 0.0375 0.0324 2324 
ln_CAPE negative* 0.0235 0.0014 0.0456 0.0374 2324 
CAPE depressive 0.0277 0.0095 0.0459 0.0029 2328 
ln_CAPE depressive* 0.0297 0.0096 0.0497 0.0037 2328 
CAPE total 0.0206 0.0074 0.0337 0.0021 2328 
ln_CAPE total* 0.0306 0.0097 0.0515 0.0042 2328 
SIS-R positive 0.0294 0.0142 0.0445 0.0001 2416 
ln_SIS-R positive* 0.0593 0.0246 0.0940 0.0008 2416 
SIS-R negative 0.0089 -0.0015 0.0193 0.0936 2415 
ln_SIS-R negative* 0.0197 -0.0029 0.0423 0.0880 2415 
SIS-R total 0.0188 0.0077 0.0300 0.0009 2416 
ln_SIS-R total* 0.0372 0.0133 0.0610 0.0022 2416 
Cognitive score -0.1465 -0.5360 0.2431 0.4612 2357 
ln_Cognitive score* 0.0041 -0.0065 0.0147 0.4474 2357 
 
* = log-transformed measure 
B=regression coefficient from multilevel model 
95% CI = 95% confidence interval 
P = p-value 
#N = number of observations in 985 individuals interviewed three times in 6 years 
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Table 8. Genetic Risk and Outcome of Psychosis (GROUP) sample: Associations between polygenic risk score and measures of psychopathology, by group* 
Psychopathology measure Stratified association of psychopathology 
measure with polygenic risk score 
Association of log-transformed 
psychopathology measure with polygenic 
risk score 
Group B (95% CI) p N B (95% CI) p N# 
CAPE positive Healthy comparison -0.0067 -0.0128 -0.0006 0.0312 2324 -0.0446 -0.0822 -0.0070 0.0201 2324 
Sibling 0.0058 0.0013 0.0104 0.0120 2324 0.0385 0.0104 0.0666 0.0072 2324 
CAPE negative Healthy comparison -0.0072 -0.0218 0.0075 0.3362 2324 -0.0105 -0.0285 0.0076 0.2551 2324 
Sibling 0.0124 0.0015 0.0233 0.0257 2324 0.0130 -0.0004 0.0265 0.0577 2324 
CAPE depressive Healthy comparison -0.0056 -0.0205 0.0092 0.4588 2328 -0.0051 -0.0215 0.0112 0.5377 2328 
Sibling 0.0221 0.0110 0.0332 0.0001 2328 0.0245 0.0123 0.0367 0.0001 2328 
CAPE total Healthy comparison -0.0068 -0.0175 0.0038 0.2094 2328 -0.0106 -0.0277 0.0064 0.2219 2328 
Sibling 0.0137 0.0057 0.0217 0.0007 2328 0.0200 0.0072 0.0327 0.0021 2328 
SIS-R positive Healthy comparison -0.0097 -0.0221 0.0026 0.1229 2416 -0.0179 -0.0462 0.0105 0.2165 2416 
Sibling 0.0196 0.0103 0.0289 0.0000 2416 0.0414 0.0202 0.0626 0.0001 2416 
SIS-R negative Healthy comparison -0.0014 -0.0099 0.0071 0.7476 2415 -0.0050 -0.0235 0.0135 0.5946 2415 
Sibling 0.0075 0.0011 0.0139 0.0211 2415 0.0147 0.0008 0.0285 0.0381 2415 
SIS-R total Healthy comparison -0.0055 -0.0146 0.0036 0.2356 2416 -0.0109 -0.0303 0.0086 0.2744 2416 
Sibling 0.0133 0.0065 0.0202 0.0001 2416 0.0263 0.0117 0.0409 0.0004 2416 
Cognitive score Healthy comparison 0.0344 -0.2845 0.3534 0.8324 2357 -0.0011 -0.0098 0.0076 0.8081 2357 
Sibling -0.1120 -0.3505 0.1265 0.3573 2357 0.0030 -0.0035 0.0095 0.3599 2357 
 
* as derived from linear combination of terms in the model with the interaction 
B=regression coefficient from multilevel model 
95% CI = 95% confidence interval 
P = p-value 
#N = number of observations in 985 individuals interviewed three times in 6 years 
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Fig. 1. PRS scatterplots with regression line for CAPE (Fig. 1a), SIS-R and (Fig. 1b) and cognition (Fig. 1c) outcomes  
Fig. 1a 
 
[PLACE HERE THE 4 FIGURES FOR FIGURE 1A: FIG_1A_CAPEPOS, FIG_1A_CAPENEG, FIG_1A_CAPEDEP, FIG_1A_CAPETOT] 
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Fig. 1b 
[PLACE HERE THE 3 FIGURES FOR FIGURE_1B: FIG_1B_SISPOS, FIG_1B_SISNEG, FIG_1B_SISTOT] 
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Fig. 1c 
  
[PLACE HERE THE 2 FIGURES FOR FIGURE_1C: FIG_1C_TCOG, FIG_1C_BEADS] 
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